Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 4/20 | 0.69 |
| ▸ | LDLR | P01130 | 1/20 | 0.67 |
| ▸ | KIT | P10721 | 1/20 | 0.67 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.67 |
| ▸ | ABL1 | P00519 | 8/20 | 0.67 |
| ▸ | BCR | P11274 | 7/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.65 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.65 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.65 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.62 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.61 |
| ▸ | RAF1 | P04049 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30211962 | 1.00 | NR2E1 (0.69) | NR2E1LDLRKITPCSK9ABL1 | |
| SCHEMBL13659898 | 0.88 | NR2E1 (0.77) | NR2E1LDLRKITPCSK9ABL1 | |
| SCHEMBL4254144 | 0.88 | NR2E1 (0.73) | NR2E1LDLRKITPCSK9ABL1 | |
| SCHEMBL28971895 | 0.88 | NR2E1 (0.68) | NR2E1LDLRKITPCSK9ABL1 | |
| SCHEMBL4254143 | 0.86 | NR2E1 (0.71) | NR2E1LDLRKITPCSK9ABL1 | |
| SCHEMBL589522 | 0.86 | NR2E1 (0.73) | NR2E1LDLRKITPCSK9ABL1 | |
| SCHEMBL29493483 | 0.86 | NR2E1 (0.73) | NR2E1LDLRKITPCSK9ABL1 | |
| SCHEMBL24532047 | 0.86 | NR2E1 (0.73) | NR2E1LDLRKITPCSK9ABL1 | |
| SCHEMBL24070143 | 0.85 | DDR1 (0.65) | NR2E1LDLRKITPCSK9ABL1 | |
| SCHEMBL30211927 | 0.85 | DDR1 (0.65) | NR2E1LDLRKITPCSK9ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | disclosed |
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | disclosed |
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | disclosed |
| CN-115697485-A | Benzylamine derivatives as DDR inhibitors | 奇斯药制品公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021239643-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | DDR2, DDR1, DDRGK1 | NR2E1 134/4885LDLR 469/4885KIT 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.